Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,472
Recruiting: 1,283
Ph III recruiting: 130
Growth YoY: +4.1%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,642)

clinicaltrialsPublishedShowing 251–300 of 1,370 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04626791	Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma	active not recruiting	Phase 2	41	Academic and Community Cancer Research UnitedOTHER	1	Aug 25, 2026	clinicaltrials
NCT04851119	Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	recruiting	Phase 1 / Phase 2	147	Children's Oncology GroupNETWORK	1	Aug 25, 2026